Participated · Series B · Aug 2026

InduPro uses a proprietary proximity-guided platform to map spatial organization of proteins on the cell surface and discover selective co-target pairs for therapeutic development. Its lead program, IDP-001, is a potential first-in-class proximity-based bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen (TAPA-E1). IDP-001 was designed to enhance tumor selectivity, target internalization, and antitumor efficacy while aiming to preserve tolerability, and the first patient has been dosed in its Phase 1 study. The Phase 1 trial is enrolling adults with advanced or metastatic squamous and non-squamous non-small cell lung cancer and other squamous solid tumors to evaluate safety, pharmacokinetics and preliminary antitumor activity. Beyond ADCs, InduPro is developing bispecific antibodies including antibody-drug conjugates and T-cell engagers to build a pipeline of first- and best-in-class programs. The company operates out of Seattle and Cambridge, Mass., and is advancing both clinical and preclinical programs supported by venture and strategic pharma investors.

Participated · Series A · Jul 2026

Throne Science makes a discreet sensor that attaches to standard toilets and, combined with an AI-powered companion app, passively tracks bathroom habits to surface patterns in digestive health, hydration status, and urinary function. The company was founded in 2023, is based in Austin, Texas, and launched to consumers in March 2026. In July it introduced a beta Gut Health AI coach that lets users ask questions about their gut health data and receive personalized feedback. Throne has hired leaders from consumer wearable and health tech companies and added medical advisors and a chief of science to its team. Financially, Throne announced a $10 million Series A to support personnel growth and R&D. Its stated long-term mission is to develop the technology into a home-based continuous screener for early signs of colorectal cancer and cancers of the urinary tract.

Participated · Series A · May 2026

GridCARE develops the Energize platform, which uses physics-based AI models to evaluate grid conditions—congestion, outages, weather, and demand fluctuations—in real time to locate underutilized power capacity. The company positions this approach as a way to shorten interconnection timelines for large data centers and AI facilities from years to months by unlocking existing grid capacity. GridCARE reports active projects across more than a dozen markets representing over 2 gigawatts of prospective AI compute capacity and cites a Portland General Electric collaboration that identified a pathway to unlock more than 400 megawatts with 80 megawatts expected online in 2026. Co-founder and CTO Ram Rajagopal is a Stanford professor on leave, and the company emphasizes working collaboratively with utilities. GridCARE frames the market opportunity around a “Time-to-Energize Crisis,” arguing power availability is a growing bottleneck for AI expansion. Financially, the company recently raised a $64 million Series A in an oversubscribed round that materially increased its valuation versus a round less than a year earlier.

Participated · Seed · Apr 2026

Ultralight, formerly Vibrant Practice, builds an AI-native vertical SaaS operating system for clinicians running functional, integrative, or longevity-focused practices. Its platform unifies electronic health records, practice management, and patient engagement while natively integrating AI to automate routine administrative tasks and surface deep clinical insights. The company positions its product to enable clinicians to focus on high-touch care by reducing operational overhead. Ultralight plans to use its newly raised seed capital to accelerate development of its AI-powered capabilities and product expansion. The company is headquartered in San Francisco, California. The reporting does not disclose revenue, user counts, or other operating metrics.

Participated · Series A · Apr 2026

Stipple Bio leverages its Pointillist Platform to discover tumor-specific cell surface epitopes and develop precision oncology medicines designed to minimize on-target/off-tumor toxicity. Its lead candidate, STP-100, is a novel antibody-drug conjugate (ADC) incorporating tumor-specific binders and is expected to enter clinical studies in early 2027. The company plans to use its Series A proceeds to advance STP-100 into multiple early-stage clinical trials and to expand its pipeline by identifying additional high therapeutic-index targets. Stipple Bio was founded in 2022 by Dr. Aaron Ring and Dr. Aashish Manglik and is led by CEO Jeff Landau. The company recently added Derek DiRocco, PhD and Thilo Schroeder, PhD to its board and retains board members including Vineeta Agarwala and Greg Verdine. Stipple Bio raised $100M in its Series A round announced in April 2026.